---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-114660"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2025-11-20T23:59:59+00:00"
generated_at: "2026-05-16T18:07:24.684267+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Edgewise Therapeutics appoints Christopher Martin to Board of Directors

## Summary
- Martin, former CCO of Verona Pharma (acquired by Merck for ~$10B), joins as Class I director.
- Appointment effective November 19, 2025; term expires at 2028 annual meeting.
- Receives $40k annual cash retainer and ~$700k stock option grant (monthly vest over 3 years).
- Board cites Martin's commercial launch expertise as critical for Becker MD launch and CV Phase 3.

## SEC filing metadata
- accession: 0001104659-25-114660
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2025-11-20T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000110465925114660/0001104659-25-114660-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000110465925114660/tm2531112d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-114660
- JSON: https://secwatch.observer/filing/0001104659-25-114660.json
- Plain text: https://secwatch.observer/filing/0001104659-25-114660.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.